Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

CD19 Protein (AA 20-291) (His tag,FITC)

CD19 Origine: Humain Hôte: HEK-293 Cells Recombinant > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
N° du produit ABIN7274067
  • Antigène Voir toutes CD19 Protéines
    CD19 (CD19 Molecule (CD19))
    Type de proteíne
    Recombinant
    Attributs du protein
    AA 20-291
    Origine
    • 30
    • 6
    • 4
    • 3
    • 3
    • 1
    • 1
    • 1
    Humain
    Source
    • 25
    • 6
    • 5
    • 3
    • 3
    • 1
    • 1
    HEK-293 Cells
    Purification/Conjugué
    Cette CD19 protéine est marqué à la His tag,FITC.
    Fonction
    FITC-Compatible Human CD19 Protein
    Séquence
    Pro20-Lys291
    Attributs du produit
    FITC-Compatible Human CD19 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Pro20-Lys291.
    Pureté
    > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
    Stérilité
    0.22 μm filtered
    niveau d'endotoxine
    Less than 1EU per μg by the LAL method.
  • Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Supplied as 0.22 μm filtered solution in PBS ( pH 7.4).
    Stock
    -80 °C
    Stockage commentaire
    Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
    Date de péremption
    12 months
  • Antigène
    CD19 (CD19 Molecule (CD19))
    Autre désignation
    CD19 (CD19 Produits)
    Synonymes
    B4 Protein, CVID3 Protein, AW495831 Protein, CD19 Protein, CD19 molecule Protein, CD19 antigen Protein, CD19 Protein, Cd19 Protein
    Sujet
    CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95 % B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging.
    Poids moléculaire
    60.1 kDa. Due to glycosylation, the protein migrates to 68-72 kDa based on Tris-Bis PAGE result.
    Pathways
    Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway
Vous êtes ici: